Capacitive hyperthermia as an alternative to brachytherapy in DNA damages of human prostate cancer cell line (DU-145)

Potentiating prostate cancer immunotherapy with oncolytic viruses

Myeloid and plasmacytoid dendritic cell vaccinations for castration-resistant prostate cancer patients.

Genetically engineered oncolytic Newcastle disease virus mediates cytolysis of prostate cancer stem like cells

Prostate cancer immunotherapy, particularly in combination with androgen deprivation or radiation treatment. Customized pharmacogenomic approaches to overcome immunotherapy cancer resistance

Current status of clinical trials assessing oncolytic virus therapy for urological cancers

A comprehensive review of immunotherapies in prostate cancer

Dendritic cell vaccination in combination with docetaxel for patients with metastatic castration-resistant prostate cancer: A randomized phase II study

Expression of CD14, IL10, and Tolerogenic Signature in Dendritic Cells Inversely Correlate with Clinical and Immunologic Response to TARP Vaccination in Prostate Cancer Patients

The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of prostate carcinoma